Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NETWORK 3OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 48Lymphoma 34Lymphoma, Large B-Cell, Diffuse 32Lymphoma, Non-Hodgkin 23Osteosarcoma 21Hodgkin Disease 17Testicular Neoplasms 16Burkitt Lymphoma 13Testicular Germ Cell Tumor 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Ovarian Neoplasms 12Teratoma 9Neuroectodermal Tumors, Primitive, Peripheral 9Lymphoma, Large-Cell, Immunoblastic 9Lymphoma, Follicular 9Neuroblastoma 8Lymphoma, Large-Cell, Anaplastic 8Central Nervous System Neoplasms 8Recurrence 7Lymphoma, Mantle-Cell 7Lymphoma, B-Cell 7Leukemia 7Endodermal Sinus Tumor 7Seminoma 6Rhabdomyosarcoma 6Lymphoma, B-Cell, Marginal Zone 6Breast Neoplasms 6Small Cell Lung Carcinoma 5Neoplasms, Germ Cell and Embryonal 5Neoplasms 5

Interventions

pembrolizumab 2pazopanib 2Sunitinib 2Radiotherapy 2selinexor 1lentiviral minigene vaccine of COVID-19 coronavirus 1ixazomib 1cediranib 1Zoledronic Acid 1Radiotherapy, Intensity-Modulated 1Radiation Dose Hypofractionation 1Polymerase Chain Reaction 1Nivolumab 1Neoadjuvant Therapy 1Methotrexate 1Ifosfamide 1Gene Expression Profiling 1Gemcitabine 1Epirubicin 1Doxorubicin 1Diathermy 1Dasatinib 1Dactinomycin 1Dacarbazine 1Cisplatin 1Blotting, Western 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Sarcoma, Alveolar Soft Part × Ifosfamide × Clear all
NCT03277924 2024-08-13

ImmunoSarc

Grupo Espanol de Investigacion en Sarcomas

Phase 1/2 Completed
197 enrolled
Sarcoma

Chondrosarcoma, Extraskeletal Myxoid, Bone Neoplasms, Chondrosarcoma, Hemangioendothelioma, Hemangiosarcoma, Leiomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Hemangioendothelioma, Epithelioid, Histiocytoma, Malignant Fibrous, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡